

## **PIDG - Patient-centric Delivery Systems**

### **Research Outputs**

1. Song, Y., Lwin, E., Ellis, D., Turner, S., Williams, D., and Garg, S. (2020) Stability evaluation of an extemporaneously compounded carbimazole oral suspension, *Journal of Pharmacy Practice and Research* 50, 329-334.
2. Leggett, C., Lwin, E., Ritchie, U., Song, Y., Gerber, C., Turner, S., Hague, W., Stark, M. J., Upton, R., and Garg, S. (2020) Perindopril in Breast Milk and Determination of Breastfed Infant Exposure: A Prospective Observational Study, *Drug Design Development and Therapy* 14, 961.
3. Costabile, M., Day, C., Garg, S., and Aldous, G. (2020) Development, implementation, and evaluation of an innovative, project-based assignment for final year pharmacy students, relating to novel drug delivery systems, *Pharmacy Education* 20, 67-75.
4. Afinjuomo, F., Fouladian, P., Barclay, T., Song, Y., Petrovski, N., and Garg, S. (2020) Influence of oxidation on the physicochemical properties of oxidized inulin, *Polymers* 12, Article 1025.
5. Bergamin, A., Mantrzioris, E., Cross, G., Deo, P., Garg, S., and Hill, A. M. (2019) Nutraceuticals: Reviewing their Role in Chronic Disease Prevention and Management, *Pharmaceutical Medicine* 33, 291-309.
6. Barclay, T., Day, C., Petrovski, N., and Garg, S. (2019) Review of polysaccharide particle-based functional drug delivery, *Carbohydrate Polymers* 221, 94-112.
7. Song, Y., Chin, Z., Ellis, D., Lwin, E., Turner, S., Williams, D., and Garg, S. (2018) Stability of an extemporaneously compounded minoxidil oral suspension, *American Journal of Health Systems Pharmacy* 75, 309-315.
8. Sarwal, A., Singh, G., Singh, K., and Garg, S. (2018) Recent Interventions for Nanotechnology Based Drug Products: Insights into the Regulatory Aspects, *Current Pharmaceutical Design* 24, 5219-5228.
9. Parikh, A., Kathwala, K., Li, J., Chen, C., Shan, Z., Cao, X., Wang, Y. J., Garg, S., and Zhou, X. F. (2018) Self-nanomicellizing solid dispersion of Edaravone: Part I: Oral bioavailability improvement, *Drug Design Development and Therapy* 12, 2051-2069.
10. Parikh, A., Kathwala, K., Li, J., Chen, C., Shan, Z., Cao, X., Wang, Y. J., Garg, S., and Zhou, X. F. (2018) Self-nanomicellizing solid dispersion of Edaravone: Part II: in-vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model, *Drug Design Development and Therapy* 12, 2111-2128.
11. Parikh, A., Kathwala, K., Li, J., Chen, C., Cao, X., Zhou, X. F., and Garg, S. (2018) Curcumin-loaded self-nanomicellizing solid dispersion system: Part II: In-vivo safety and efficacy assessment against behavior deficit in Alzheimer disease Drug Delivery and Translational Research 8, 1406-1420.
12. Parikh, A., Kathwala, K., Li, J., Chen, C., Cao, X., Zhou, X. F., and Garg, S. (2018) Curcumin-loaded self-nanomicellizing solid dispersion system: part I: development, optimization, characterization and oral bioavailability Drug Delivery and Translational Research 13, 1389-1405.

13. Lwin, E., Leggett, C., Ritchie, U., Gerber, C., Song, Y., Hague, W., Upton, R., and Garg, S. (2018) Transfer of rosuvastatin into breast milk: LC-MS/MS methodology and clinical recommendations, *Drug Design Development and Therapy* 2018, 3645-3651.
14. Lwin, E., Gerber, C., Leggett, C., Song, Y., Ritchie, U., Turner, S., Hague, B., Upton, R., and Garg, S. (2018) Estimation of Atenolol Transfer into Milk and Infant Exposure during Its Use in Lactating Women, *J Human Lactation* 34, 592-599.
15. Kosari, S., Walker, E. J., Anderson, C., Peterson, G. M., Naunton, M., Castillo, E. M., Garg, S., and Thomas, J. (2018) Power outages and refrigerated medicines: the need for better guidelines, awareness and planning, *Journal of Clinical Pharmacy and Therapeutics* 43, 737-739.
16. Garcia, J., Garg, A., Song, Y., Fotios, A., Anderson, C., and Garg, S. (2018) Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion *Plos One* 13, 1-13.
17. Parikh, A., Kathwala, K., Garg, S., and Zhou, X. F. (2017) Novel Lipid-based Nanosystem of Edaravone: Development, Optimisation, Characterization and In-vitro/In-vivo evaluation, *Drug delivery* 24, 962-978.
18. Parikh, A., Kathwala, K., Shan, Z., Chen, C., Li, J., Tan, C. C., Garg, S., and Zhou, X. F. (2017) Enhanced oral bioavailability of edaravone and reverse cognitive deficits in an Alzheimer's disease model via a self micellizing solid dispersion approach, *Alzheimer's and Dementia* 13, 1578-1579.
19. Lwin, E. M. P., Gerber, C., Song, Y., Leggett, C., Ritchie, U., Turner, S., and Garg, S. (2017) A new LC-MS/MS bioanalytical method for Atenolol in human plasma and milk, *Bioanalysis* 9, 517-530.
20. Lwin, E., Gerber, C., Song, Y., Leggett, C., Ritchie, U., Turner, S., and Garg, S. (2017) A New LC-MS/MS Bioanalytical Method for Perindopril and Perindoprilat in Human Plasma and Milk, *Analytical and Bioanalytical Chemistry* 409, 6141-6148.
21. Uppalapati, D., Boyd, B. J., Garg, S., Travas-Sejdic, J., and Svirskis, D. (2016) Conducting polymers with defined micro- or nanostructures for drug delivery, *Biomaterials* 111, 149-162.
22. Parikh, A., Shan, Z., Song, Y., Kathwala, K., Tan, C. C., Garg, S., and Zhou, X. F. (2016) A novel formulation of curcumin for Alzheimer's disease (AD): an in-vitro and in-vivo evaluation, *Alzheimer's and Dementia* 12, 1024.
23. Parikh, A., Kathwala, K., Tan, C. C., Garg, S., and Zhou, X. F. (2016) Development of a novel oral delivery system of edaravone for enhancing bioavailability, *Int. J. Pharmaceutics* 515, 490-500, (\*equal corresponding author).
24. Narayan, R., Singh, M., Ranjan, O. P., Nayak, Y., Garg, S., Shavi, G. V., and Nayak, U. Y. (2016) Development of risperidone liposomes for brain targeting through intranasal route, *Life Sciences* 163, 38-45.
25. Lwin, E., Ellis, D., Song, Y., Turner, S., and Garg, S. (2016) Stability studies of extemporaneously compounded clobazam oral suspension, *Annals of Pharmacotherapy* 50, 155-156.

26. Simpson, B. S., Luo, X., Wang, J., Song, Y., Claudie, D. J., Garg, S., Smith, N. M., Mckinnon, R. A., and Semple, S. J. (2015) Development and evaluation of a topical anti-inflammatory preparation containing Dodonaea polyandra extract Journal of Pharmacy and Pharmaceutical Sciences 18, 578-599.
27. Hotham, L., Pariyadan, M. V., Turner, S., and Garg, S. (2015) Ethics and compliance hurdles in conducting multicentre low-risk research, The Medical Journal of Australia 203, 324-325.
28. Garg, A., Chan, D., Ambados, F., Lwin, E., Song, Y., and Garg, S. (2015) Penicillin stability in prefilled syringes for the purpose of skin testing for drug allergy, Journal of Allergy and Clinical Immunology: In Practice 3, 599-601.
29. Wahlster, P., Scahill, S., Garg, S., and Babar, Z. U. D. (2014) Identifying stakeholder opinion regarding access to "high-cost medicines": A systematic review of the literature, Central European Journal of Medicine 9, 513-527.
30. Yang, Y., Garg, S., Sharma, M., and Svirskis, D. (2013) Electrically switchable polypyrrole film for the tunable release of progesterone, Therapeutic Delivery 4, 307-313.
31. Sharma, M., Waterhouse, G. I. N., Loader, S. W. C., Garg, S., and Svirskis, D. (2013) High surface area polypyrrole scaffolds for tunable drug delivery, International Journal of Pharmaceutics 443, 163-168.
32. Lockhart, M. M., Babar, Z. U. D., Carswell, C., and Garg, S. (2013) New Zealand's drug development industry, International Journal of Environmental Research and Public Health 10, 4339-4351.
33. Jin, Y., Zhang, W. Y., Meng, Q. F., Li, D. H., Garg, S., Teng, L. R., and Wen, J. Y. (2013) Forced degradation of flavonol glycosides extracted from Ginkgo biloba, Chemical Research in Chinese Universities 29, 667-670.
34. Jin, Y., Wen, J. Y., Garg, S., Liu, D., Zhou, Y. L., Teng, L. R., and Zhang, W. Y. (2013) Development of a novel niosomal system for oral delivery of Ginkgo biloba extract, International Journal of Nanomedicine 8, 421-430.
35. Garg, S., Sabri, D., Kanji, J., Rakkar, P. S., Lee, Y., Naidoo, N., and Svirskis, D. (2013) Evaluation of vitamin D medicines and dietary supplements and the physicochemical analysis of selected formulations, Journal of Nutrition Health & Aging 17, 158-161.
36. Garg, S., Hasan, R., Scahill, S., and Babar, Z. U. D. (2013) Investigating inspection practices of pharmaceutical manufacturing facilities in selected Arab countries: views of inspectors and pharmaceutical industry employees, Eastern Mediterranean Health Journal 19, 919-929.
37. Babar, Z., Scahill, S., Garg, S., and Akhlaq, M. (2013) A bibliometric review of pharmacy education literature in the context of low and middle-income countries, Currents in Pharmacy Teaching and Learning 5, 218-232.
38. Babar, Z., Pengelly, K., Scahill, S., Garg, S., and Shaw, J. (2013) Migrant health in New Zealand: exploring issues concerning "medicines access and use", Journal of Pharmaceutical Health Services Research 4, 41-49.

39. Siddalingam, R., Keat, N. W., and Garg, S. (2012) Self-nanoemulsifying drug delivery systems of Valsartan: preparation and in-vitro characterization, International Journal of Drug Delivery 4, 153-163.
40. Lockhart, M. M., Babar, Z. U. D., and Garg, S. (2012) Drug development and research in New Zealand: policies affecting the industry, Drug Development Research 73, 1-10.
41. Lockhart, M. M., Babar, Z. U. D., and Garg, S. (2012) Drug development in NZ: can a country be a cluster?, Drug Development Research 73, 51-58.
42. Svirskis, D., Travas-Sejdic, J., and Garg, S. (2011) A Stability Indicating HPLC Method for the Determination of Electrochemically Controlled Release of Risperidone, Journal of Chromatographic Science 49, 780-785.
43. Sharma, P., Zujovic, Z. D., Bowmaker, G. A., Denny, W. A., and Garg, S. (2011) Evaluation of a crystalline nanosuspension: Polymorphism, process induced transformation and in vivo studies, International Journal of Pharmaceutics 408, 138-151.
44. Lyn, L. Y., Sze, H. W., Rajendran, A., Adinarayana, G., Dua, K., and Garg, S. (2011) Crystal modifications and dissolution rate of piroxicam, Acta Pharmaceutica 61, 391-402.
45. Lockhart, M. M., Babar, Z. U. D., and Garg, S. (2011) Clinical Trials in New Zealand: Progress, People, and Policies, Drug Development Research 72, 299-304.
46. Garg, A., Garg, S., and She, R. W. (2011) Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation, Burns 37, 1150-1153.
47. Svirskis, D., Wright, B. E., Travas-Sejdic, J., Rodgers, A., and Garg, S. (2010) Evaluation of physical properties and performance over time of an actuating polypyrrole based drug delivery system, Sensors and Actuators B-Chemical 151, 97-102.
48. Svirskis, D., Wright, B. E., Travas-Sejdic, J., Rodgers, A., and Garg, S. (2010) Development of a Controlled Release System for Risperidone Using Polypyrrole: Mechanistic Studies, Electroanalysis 22, 439-444.
49. Svirskis, D., Travas-Sejdic, J., Rodgers, A., and Garg, S. (2010) Electrochemically controlled drug delivery based on intrinsically conducting polymers, Journal of Controlled Release 146, 6-15.
50. Lockhart, M. M., U-D Babar, Z., and Garg, S. (2010) New Zealand's drug development industry--strengths and opportunities, The New Zealand Medical Journal (Online) 123, 52-58.
51. Lockhart, M., Babar, Z. U. D., and Garg, S. (2010) Evaluation of policies to support drug development in New Zealand, Health Policy 96, 108-117.
52. Svirskis, D., Travas-Sejdic, J., Rodgers, A., and Garg, S. (2009) Polypyrrole Film as a Drug Delivery System for the Controlled Release of Risperidone, In Advanced Materials and Nanotechnology, Proceedings (Hendy, S. C., and Brown, I. W. M., Eds.), pp 36-39, Amer Inst Physics, Melville.
53. Sharma, P., Denny, W. A., and Garg, S. (2009) Effect of wet milling process on the solid state of indomethacin and simvastatin, International Journal of Pharmaceutics 380, 40-48.
54. Garg, S., Svirskis, D., Al-Kabban, M., Farhan, S., Komeshi, M., Lee, J., Liu, Q., Naidoo, S., and Kairuz, T. (2009) Chemical stability of extemporaneously compounded omeprazole

- formulations: a comparison of two methods of compounding, *Int. J. Pharm. Compounding* 13, 250-253.
55. Garg, S., Svirskis, D., Myftiu, J., Behayaa, M., Shahin, D., Thrimawithana, T., Vidicki, A., and Kairuz, T. (2008) Properties of a formulated pediatric phenobarbitone oral liquid, *J. Pharmacy Practice and Research* 38, 28-31.
  56. Butcher, J. C., Garg, S., Kim, D., and Sharma, P. (2008) A modified approach to predict dissolution and absorption of polydisperse powders, *Pharmaceutical Research* 25, 2309-2311.
  57. Kairuz, T., Svirskis, D., Myftiu, J., Behayaa, M., Shahin, D., Thrimawithana, T., Vidicki, A., and Garg, S. (2007) Quality assurance in extemporaneously compounded formulations: a titration method for Ursodeoxycholic Acid, *Hospital Pharmacist* 14, 304-306
  58. Kairuz, T., Myftiu, J., Svirskis, D., Hasan, F., Lal, A., Patel, R., Kumar, K., Chhim, S., Singh, R., and Garg, S. (2007) Extemporaneous compounding in New Zealand hospitals, *Int. J. Pharm. Practice* 15, 129-131.
  59. Kairuz, T., Gargiulo, D., Bunt, C., and Garg, S. (2007) Quality, safety, and efficacy in the off-label use of medicines, *Current drug safety* 2, 89-95.
  60. Kairuz, T., Chhim, S., Hasan, F., Kumar, K., Lal, A., Patel, R., Singh, R., Dogra, M., and Garg, S. (2007) Extemporaneous compounding in a sample of New Zealand hospitals: a retrospective survey, *The New Zealand Medical Journal* 120, 1-9.
  61. Garg, S., and Kumar, G. (2007) Development and evaluation of a buccal bioadhesive system for smoking cessation therapy, *Pharmazie* 62, 266-272.
  62. Anand, V., Kandarapu, R., and Garg, S. (2007) Preparation and evaluation of taste masked orally disintegrating tablets of Prednisolone, *Asian Journal of Pharmaceutical Sciences* 2, 213-224.
  63. Verma, R. K., and Garg, S. (2005) Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing, *Journal of Pharmaceutical and Biomedical Analysis* 38, 633-644.
  64. Varma, M. V. S., Kaushal, A. M., and Garg, S. (2005) Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices, *Journal of Controlled Release* 103, 499-510.
  65. Verma, R. K., and Garg, S. (2004) Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations, *Journal of Pharmaceutical and Biomedical Analysis* 35, 449-458.
  66. Verma, R. K., and Garg, S. (2004) Development and evaluation of the osmotically controlled oral drug delivery system of glipizide, *European Journal of Pharmaceutics and Biopharmaceutics* 57, 513-525.
  67. Verma, R. K., Arora, S., and Garg, S. (2004) Osmotic pumps in drug delivery, *Critical Reviews in Therapeutic Drug Carrier Systems* 21, 477-520.
  68. Varma, M. V. S., Kaushal, A. M., and Garg, S. (2004) Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations, *Journal of Pharmaceutical and Biomedical Analysis* 36, 669-674.

69. Varma, M. V. S., Kaushal, A., Garg, A., and Garg, S. (2004) Factors affecting mechanism and kinetics of drug release from matrix based oral controlled release drug delivery systems, Am. J. Drug Delivery 2, 43-57.
70. Verma, R. K., Kaushal, A. M., and Garg, S. (2003) Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology, International Journal of Pharmaceutics 263, 9-24.
71. Vasir, J. K., Tambwekar, K., and Garg, S. (2003) Bioadhesive microspheres as a controlled drug delivery system, International Journal of Pharmaceutics 255, 13-32.
72. Tambwekar, K. R., Kakariya, R. B., and Garg, S. (2003) A validated high performance liquid chromatographic method for analysis of nicotine in pure form and from formulations, Journal of Pharmaceutical and Biomedical Analysis 32, 441-450.
73. Kaushal, A., and Garg, S. (2003) Minimizing bioavailability variations with oral controlled release formulations, Am. J. Drug Delivery 1, 103-112.
74. Kaushal, A., and Garg, S. (2003) An update on osmotic drug delivery patents, Pharm. Tech. 27, 38-97.
75. Kannan, V., Kandarapu, R., and Garg, S. (2003) Optimization techniques for the design and development of novel drug delivery systems part II, Pharm. Tech. 27, 102-118.
76. Kannan, V., Kandarapu, R., and Garg, S. (2003) Optimization techniques for the design and development of novel drug delivery systems, part I, Pharm. Tech. 27, 74-90.
77. Verma, R. K., Krishna, D. M., and Garg, S. (2002) Formulation aspects in the development of osmotically controlled oral drug delivery systems, Journal of Controlled Release 79, 7-27.
78. Verma, R. K., and Garg, S. (2002) A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations, Journal of Pharmaceutical and Biomedical Analysis 30, 583-591.
79. Nanda, A., Raghupathi, K., and Garg, S. (2002) An update on taste masking technologies for oral pharmaceuticals, Ind. J. Pharm. Sci. 64, 10-17.
80. Gupta, P., Vermani, K., and Garg, S. (2002) Hydrogels: from controlled release to pH-responsive drug delivery, Drug Discovery Today 7, 569-579.
81. Gupta, P., and Garg, S. (2002) Recent advances in semi-solid dosage forms for dermatological applications, Pharm. Tech. March, 144-162.
82. Garg, S., Vermani, K., Kohli, G., Kandarapu, R., Zaneveld, L. J., and et al. (2002) Survey of vaginal formulations available on the Indian market: physicochemical characterization of selected products, Int. J. Pharm. Medicine 16, 141-152.
83. Garg, A., Aggarwal, S., Garg, S., and Singla, A. K. (2002) Spreading of semi-solid formulations: an update, Pharm. Tech. Sep., 84-105.
84. Arora, P., Sharma, S., and Garg, S. (2002) Permeability issues in nasal drug delivery, Drug Discovery Today 7, 967-975.
85. Verma, R. K., and Garg, S. (2001) Current status of drug delivery technologies and future directions, Pharm. Tech. 25, 1-14.
86. Tambwekar, K., and Garg, S. (2001) Proper management of laboratory notebook: a step towards success, Pharm. Tech. Asia, 36-40.

87. Anand, V., Kandarapu, R., and Garg, S. (2001) Ion-exchange resins: carrying drug delivery forward, *Drug Discovery Today* 6, 905-914.
88. Verma, R. K., Mishra, B., and Garg, S. (2000) Osmotically controlled oral drug delivery, *Drug Development and Industrial Pharmacy* 26, 695-708.
89. Verma, R. K., and Garg, S. (2000) Delivery of Glipizide using controlled porosity osmotic pumps, *Indian J. Pharm. Sci.* 62, 528-529.
90. Geetha, T., and Garg, S. (1999) Recent developments in tablet excipients, *Int. J. Pharm. Excipients* 1, 49-56.
91. Gupta, A., Garg, S., and Khar, R. K. (1994) Interpolymer complexation and its effect on bioadhesive strength and dissolution characteristics of buccal delivery systems, *Drug Development and Industrial Pharmacy* 20, 315-325.
92. Talwar, G. P., Singh, O., Pal, R., Chatterjee, N., Upadhyay, S. N., Kaushic, C., Garg, S., Kaur, R., Singh, M., Chandrasekhar, S., and Gupta, A. (1993) A birth-control vaccine is on the horizon for family-planning, *Annals of Medicine* 25, 207-212.
93. Gupta, A., Garg, S., and Khar, R. K. (1993) Measurement of bioadhesive strength of mucoadhesive buccal tablets: design of an in vitro assembly, *Indian Drugs* 30, 152-155.
94. Garg, S., and Sharma, S. N. (1993) Development of spray-on bandage with hemostatic activity, *Indian J. Hematology* 11, 90-94.
95. Garg, S. (1993) Development of aerosol valve holder for repeated use, *Indian Drugs* 30, 527-528.
96. Gupta, A., Garg, S., and Khar, R. K. (1992) Mucoadhesive buccal drug delivery systems, *Indian Drugs* 29, 586-593.
97. Garg, S., and Sharma, S. N. (1992) Development of medicated aerosol dressings of chlorhexidine acetate with hemostatics, *Pharmazie* 47, 924-926.